Abstract
Abstract Bronchiectasis unrelated to cystic fibrosis is an important cause of respiratory morbidity and mortality in children globally. A vicious cycle of infection, muco-ciliary impairment and chronic inflammation leads to structural damage and irreversible dilatation of bronchi. A wide range of underlying conditions can lead to bronchiectasis and it is vital to investigate these children thoroughly. Management should be proactive and aim at minimizing daily symptoms, maximizing quality of life and preventing decline in lung functions. Central to management of bronchiectasis is identification and treatment of the underlying condition. Prompt treatment of exacerbations with antimicrobials and limiting further damage by strategies like immunization are other important aspects. Macrolides may help cut down exacerbations and reduce airway inflammation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
